Back to stories
Industry

OpenAI Shares Struggle to Find Buyers as Investors Pivot to Anthropic

Michael Ouroumis2 min read
OpenAI Shares Struggle to Find Buyers as Investors Pivot to Anthropic

The AI industry's investor landscape is undergoing a dramatic shift. According to a Bloomberg report published this week, OpenAI shares have fallen sharply out of favor on secondary markets — in some cases becoming nearly impossible to unload — as institutional money pivots rapidly toward Anthropic.

A Tale of Two AI Giants

Despite OpenAI's recent headline-grabbing $122 billion funding round, the mood among secondary-market participants tells a different story. Ken Smythe, founder of secondary marketplace Next Round Capital, told Bloomberg that about a half-dozen institutional investors — including hedge funds and venture capital firms holding large stakes — have approached his company in recent weeks looking to sell roughly $600 million worth of OpenAI shares.

The problem: there are few takers. "We literally couldn't find anyone in our pool of hundreds of institutional investors to take these shares," one marketplace founder reportedly said.

Anthropic Demand Surges

The contrast with Anthropic could not be starker. Hiive, another secondary marketplace, has registered more than $1.6 billion in demand for Anthropic shares, also at a premium. "The demand is one of the highest we've ever seen," said Hiive co-founder Prab Rattan.

Buyers have reportedly indicated they have $2 billion of cash ready to deploy into Anthropic, signaling deep institutional conviction in the Claude-maker's trajectory.

The Valuation Calculus

The math driving this shift is straightforward. OpenAI currently sits at an $852 billion valuation after its record-setting funding round, while Anthropic's most recent valuation stands at $380 billion. According to Augment co-founder Adam Crawley, investors are making a straightforward bet: "People are betting that Anthropic's valuation will catch up with OpenAI's."

With Anthropic approaching $19 billion in annualized revenue and OpenAI at roughly $25 billion, the revenue gap is far narrower than the valuation gap suggests, making Anthropic shares look like the better relative value play.

What This Means for the AI Race

The secondary market shift reflects broader questions about the sustainability of sky-high AI valuations and which company is best positioned for the next phase of competition. OpenAI's recent strategic decisions — including shuttering its Sora video app and pivoting heavily toward enterprise integrations — have drawn mixed reactions.

Meanwhile, Anthropic's Claude models have gained significant traction in developer and enterprise markets, and the company's positioning in the ongoing Pentagon legal battle has kept it in the spotlight.

Whether this investor sentiment shift proves prescient or premature will depend on how both companies execute in the months ahead, particularly as OpenAI prepares for a potential IPO later this year.

Learn AI for Free — FreeAcademy.ai

Take "AI for Business: Practical Implementation" — a free course with certificate to master the skills behind this story.

More in Industry

Google Ships Antigravity 2.0: A Standalone Agent Platform That Retires the Gemini CLI
Industry

Google Ships Antigravity 2.0: A Standalone Agent Platform That Retires the Gemini CLI

At I/O 2026, Google relaunched Antigravity as a standalone agent-orchestration platform with a CLI that replaces the Gemini CLI, an SDK, Managed Agents in the Gemini API, and an enterprise tier — all defaulting to Gemini 3.5 Flash.

10 min ago2 min read
Alibaba's Zhenwu M890 Claims 3x Nvidia's H20, Ships With Qwen 3.7-Max
Industry

Alibaba's Zhenwu M890 Claims 3x Nvidia's H20, Ships With Qwen 3.7-Max

Alibaba's chip unit T-Head unveiled the Zhenwu M890 AI accelerator, claiming 3x the agentic-inference performance of Nvidia's H20 and 144GB of HBM3, paired with the Qwen 3.7-Max model — a full domestic stack as US export controls tighten.

1 hours ago2 min read
Cohere Buys Reliant AI to Build 'North for Pharma' Sovereign Biopharma Agents
Industry

Cohere Buys Reliant AI to Build 'North for Pharma' Sovereign Biopharma Agents

Cohere has acquired Montréal- and Berlin-based biopharma startup Reliant AI, folding its automated research workbench into the North platform to launch 'North for Pharma' — its second acquisition in a month as it doubles down on sovereign, regulated-industry AI.

3 hours ago2 min read